John G Gerber
Affiliation: University of Colorado Health Sciences Center
- Lack of an effect of age on beta-adrenoceptor-mediated lipolysis in isolated human adipocytesJ G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, USA
J Gerontol A Biol Sci Med Sci 54:B71-7. 1999..These data suggest that neither beta 1- nor beta 2-adrenoceptor responses in human adipocytes show significant changes due to aging...
- Therapeutic drug monitoring in the treatment of HIV-infectionJohn G Gerber
Divisions of Clinical Pharmacology and Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO 80262, USA
J Clin Virol 27:117-28. 2003..At this point in time we consider TDM in the treatment of HIV-infection as experimental with significant promise for the future...
- Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber
University of Colorado Health Sciences Center, Denver, CO 80262, USA
J Acquir Immune Defic Syndr 39:307-12. 2005..The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA...
- Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401J G Gerber
University of Colorado Health Sciences Center, 4200 E 9th Avenue, Denver, CO 80262, USA
J Acquir Immune Defic Syndr 27:153-60. 2001..The effect of ritonavir 400 mg/saquinavir 400 mg twice daily on the stereoselective pharmacokinetics of methadone was examined in 12 HIV-infected, methadone-using study subjects...
- Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19John G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Chirality 16:36-44. 2004....
- Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunctionDavid L Wyles
Department of Medicine, Divisions of Infectious Diseases and Clinical Pharmacology, University of Colorado Health Sciences Center, Denver, USA
Clin Infect Dis 40:174-81. 2005....
- Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteersJennifer J Kiser
Department of Pharmaceutical Sciences, University of Colorado Denver, Denver, CO, USA
J Acquir Immune Defic Syndr 47:570-8. 2008..Tolerability and lipid changes were also assessed...
- Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
J Acquir Immune Defic Syndr 47:459-66. 2008..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
- Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugsJennifer J Kiser
Division of Clinical Pharmacology, University of Colorado Health Science Center, Denver, CO 80262, USA
Curr HIV/AIDS Rep 2:61-7. 2005..Nevertheless, there are specific clinical instances where this experimental intervention should be considered to potentially reduce toxicity and improve therapeutic outcomes...
- Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substratesShahrzad Dilmaghanian
Division of Clinical Pharmacology and Toxicology, University of Colorado Health Sciences Center, Denver, Colorado, USA
Chirality 16:79-85. 2004..Overall, levo-KTZ was 2-4-fold more active than dextro-KTZ. Therefore, levo-KTZ is a more potent inhibitor of CYP3A4 and has stronger in vitro antifungal activity. Chirality 16:79-85, 2004...
- Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavirDavid W Haas
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
J Acquir Immune Defic Syndr 50:290-3. 2009..Rifampin is the cornerstone of antituberculosis therapy, but induction of hepatic cytochrome P4503A by rifampin markedly lowers HIV protease inhibitor plasma concentrations...
- Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047Carl J Fichtenbaum
University of Cincinnati College of Medicine, Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, Ohio 45267 0405, USA
AIDS 16:569-77. 2002....
- Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infectionCarl J Fichtenbaum
Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Clin Pharmacokinet 41:1195-211. 2002....
- Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice dailyEdward P Acosta
University of Alabama at Birmingham, Birmingham, Alabama, USA
Antimicrob Agents Chemother 51:3104-10. 2007..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
- Position paper on therapeutic drug monitoring of antiretroviral agentsEdward P Acosta
Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 18:825-34. 2002..This position paper offers guidelines to aid clinicians who choose to incorporate TDM into the routine care of their patients...
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108Judith A Aberg
New York University, New York, New York, USA
AIDS 20:725-9. 2006..Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia...
- Protein binding in antiretroviral therapiesMarta Boffito
St Stephens Centre, Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom
AIDS Res Hum Retroviruses 19:825-35. 2003....
- Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherenceHulin Wu
Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
J Pharmacokinet Pharmacodyn 33:399-419. 2006..But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates...
- Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)Barbara M Gripshover
University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
Antivir Ther 11:619-23. 2006..Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses...
- The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)Arlene S Pereira
Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
J Infect Dis 186:198-204. 2002..The antiretroviral effect of APV monotherapy was related to APV concentrations...
- Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby
Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Pharmacol Ther 78:143-53. 2005..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
- The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back
Department of Pharmacology, University of Liverpool, Liverpool, UK
J Acquir Immune Defic Syndr 39:S1-23, quiz S24-25. 2005....
- Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistanceHulin Wu
Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
J Acquir Immune Defic Syndr 39:272-83. 2005..The proposed mathematic models and statistical techniques may provide a framework to simulate and predict antiviral response for individual patients...
- Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapyJennifer R King
University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama, USA
AIDS 19:1059-63. 2005..To describe the in vivo protein-binding characteristics of indinavir (IDV) in the presence of ritonavir (RTV) relative to total IDV plasma concentrations...
- Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroismDavid Dunmire
Department of Chemistry, Syracuse University, Syracuse, New York 13244 4100, USA
Chirality 17:S101-8. 2005....
- Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panelMorris Schambelan
University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
J Acquir Immune Defic Syndr 31:257-75. 2002..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
- Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicityMarshall J Glesby
AIDS Read 13:346-7. 2003
- Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta
Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
J Acquir Immune Defic Syndr 37:1358-66. 2004....
- Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult Michael P Dube
Indiana University, Indianapolis, USA
Clin Infect Dis 37:613-27. 2003
- Abacavir pharmacokinetics in hepatic dysfunctionDavid L Wyles
Clin Infect Dis 40:909-10. 2005